ArticleNeurology(R) neuroimmunology & neuroinflammation2026
Lifespan Modeling of Choroid Plexus Volume in Multiple Sclerosis and Its Dynamic Associations With Clinical, MRI, and HLA Susceptibility.
Article in Neurology(R) neuroimmunology & neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThe choroid plexus (ChP) regulates CSF production and CNS homeostasis. In multiple sclerosis (MS), ChP enlargement occurs early in the disease course, yet its normative lifespan trajectory and relationship with MS-specific features remain poorly defined. We aimed to define the normative ChP volume model, to characterize its trajectory across the healthy lifespan, and to assess ChP enlargement in MS using z-scores, evaluating associations with demographic, clinical, MRI, and genetic variables, including human leukocyte antigen (HLA) and non-HLA polygenic risk scores (PRSs).
methodsThis monocentric retrospective cross-sectional study included 461 healthy controls (HCs) and 727 patients with MS (age 18-70 years) who underwent 3T brain MRI and neurologic assessment. ChP volumes were quantified using ASCHOPLEX, normalized for head size, and modeled in HCs. We derived age-related normalized ChP volume (NChPV) trajectory across adulthood. Z-scores for patients with MS were computed. PRSs were calculated from established MS susceptibility loci, encompassing both HLA and non-HLA regions.
resultsIn HCs, normalized brain volume, lateral ventricle volume, and its squared term were independently associated with NChPV (R DISCUSSION: We provided a normative ChP volume model, characterized its trajectory across the healthy lifespan, and showed early, consistently higher ChP volume in patients with MS across ages and disease durations in cross-sectional analyses, linked to inflammatory lesion burden and HLA-mediated genetic risk. The ChP may represent a noninvasive biomarker of neuroinflammation and HLA-related immunogenetic background in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.